Drug profile

The FDA adverse-event record for Polymyxin B Sulfate;Oxytetracycline Hcl

174 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Polymyxin B Sulfate;Oxytetracycline Hcl. See the species affected, top reactions, and outcomes below.

174
adverse-event reports
3.4%
death-coded share
Unknown
most-reported species
39
Color, Abnormal - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
174
Total Reports
6
Deaths Reported
3.4%
Death Rate

Active Ingredients

Polymyxin B Sulfate;Oxytetracycline Hcl

Administration Routes

UnknownOphthalmicIntraocularTopicalOral

Species Affected

Unknown 83
Cat 71
Dog 17
Human 2
Goat 1

Most Affected Breeds

Unknown 85
Domestic Shorthair 39
Cat (other) 18
Domestic Mediumhair 4
Ragdoll 3
Chihuahua 3
Dog (unknown) 3
Retriever - Labrador 3
Bulldog 2
Siamese 2

Most Reported Reactions

Color, Abnormal 39
Underfilling, Container 17
Vomiting 16
Containers, Leaking 14
Containers, Damaged 12
Swelling around eye 10
Lack of efficacy - NOS 9
Lethargy (see also Central nervous system depression in 'Neurological') 8
Corneal ulcer 8
Swollen eye 7
Ocular discharge 7
Conjunctivitis 6

Outcome Breakdown

Ongoing
37 (40.2%)
Outcome Unknown
29 (31.5%)
Recovered/Normal
19 (20.7%)
Died
3 (3.3%)
Euthanized
3 (3.3%)
Recovered with Sequela
1 (1.1%)

Polymyxin B Sulfate;Oxytetracycline Hcl Adverse Event Insights

174 reports name Polymyxin B Sulfate;Oxytetracycline Hcl; 6 recorded a death outcome (3.4% of reported events, not a population-level mortality rate). Active ingredient: Polymyxin B Sulfate;Oxytetracycline Hcl. Administration routes: Unknown, Ophthalmic, Intraocular, Topical.

By species: Unknown (83 reports), Cat (71 reports), Dog (17 reports). By breed: Unknown (85), Domestic Shorthair (39), Cat (other) (18).

Leading clinical signs: Color, Abnormal (39), Underfilling, Container (17), Vomiting (16), Containers, Leaking (14). Outcome, 92 coded reports: Ongoing leads at 40.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.